Physician
Wagdy W. Kades, M.D. INC.
Wagdy W. Kades, M.D. INC. was paid $949K by Medicaid between Jan 2018 and Nov 2024, across 16 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 59% of everything it billed.
33Billing provider infoWAGDY W. KADES, M.D. INC.
LOS ANGELES, CA 90017
LOS ANGELES, CA 90017
33aNPI1336247717assigned 09/20/2006
33bProvider typeRheumatology Physician
28Total paid$949K
24GClaims16,378
24DCodes billed16
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rheumatology Physician providers in California
Rank by total paid#20 of 147
Median peer was paid$43K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,244 | $40K | |
| 2019 | 2,626 | $74K | |
| 2020 | 1,590 | $45K | |
| 2021 | 1,407 | $70K | |
| 2022 | 2,162 | $188K | |
| 2023 | 2,943 | $260K | |
| 2024incomplete | 3,406 | $272K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 59% | 12,141 | 12,108 | $555K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 21% | 580 | 551 | $198K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 11% | 1,211 | 1,211 | $107K |
| 99205 | Prolong outpt/office vis | 2.5% | 345 | 345 | $23K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 499 | 468 | $21K |
| 20611 | 2.1% | 667 | 454 | $20K | |
| 76881 | 1.6% | 436 | 433 | $15K | |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 51 | 50 | $3K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 34 | 34 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 164 | 164 | $2K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 28 | 15 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 64 | 64 | $173.34 |
4 more codes
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 46 | $138.01 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 84 | $136.14 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14 | $19.50 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $4.03 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKADES, WAGDY (OWNER)